To appraise the clinical and cost effectiveness of peginterferon beta-1a within its marketing authorisation for treating relapsing–remitting multiple sclerosis.
Status In progress
Process STA 2018
ID number 1521

Provisional Schedule

Expected publication 04 March 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick


Companies sponsors Biogen Idec (peginterferon beta-1a)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Association of British Neurologists
  Royal College of Physicians
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab)
  Merck (interferon beta-1a, cladribine) (not participating)
  Mylan (glatiramer acetate) (not participating)
  Novartis (interferon beta-1b, fingolimod)
  Roche (ocrelizumab) (not participating)
  Sanofi Genzyme (alemtuzumab, teriflunomide)
  Teva UK (glatiramer acetate) (not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
26 November 2019 Committee meeting: 1
29 March 2019 In progress, The final scope was issued.
29 March 2019 Invitation to participate
13 February 2019 Draft scope documents

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance